- Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021
- Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting
- Revance to Participate in the Wells Fargo Securities Healthcare Conference
- Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery
- Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update
- Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
As of last trade
Revance Therapeutics Inc (RTIG:DEU) traded at 23.80, -14.39% below its 52-week high of 27.80, set on Jul 12, 2021.
19.20Dec 03 202027.80Jul 12 2021
Markit short selling activity
|Market cap||2.01bn USD|
|EPS (TTM)||-4.72 |
Data delayed at least 15 minutes, as of Sep 22 2021 07:32 BST.